Panagora Asset Management Inc. decreased its position in Allergan PLC (NYSE:AGN) by 12.1% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 108,774 shares of the company’s stock after selling 14,931 shares during the period. Panagora Asset Management Inc.’s holdings in Allergan PLC were worth $29,155,000 at the end of the most recent quarter.
Several other institutional investors also recently bought and sold shares of the company. Ropes Wealth Advisors LLC boosted its position in Allergan PLC by 13.2% in the first quarter. Ropes Wealth Advisors LLC now owns 497 shares of the company’s stock worth $133,000 after buying an additional 58 shares during the period. Shufro Rose & Co. LLC bought a new position in Allergan PLC during the first quarter worth $200,000. Jones Financial Companies Lllp boosted its position in Allergan PLC by 34.6% in the first quarter. Jones Financial Companies Lllp now owns 864 shares of the company’s stock worth $231,000 after buying an additional 222 shares during the period. Mission Wealth Management LLC boosted its position in Allergan PLC by 12.8% in the first quarter. Mission Wealth Management LLC now owns 946 shares of the company’s stock worth $254,000 after buying an additional 107 shares during the period. Finally, Fairfield Bush & CO. boosted its position in Allergan PLC by 47.8% in the first quarter. Fairfield Bush & CO. now owns 1,104 shares of the company’s stock worth $296,000 after buying an additional 357 shares during the period.
Allergan PLC (NYSE:AGN) traded up 4.43% during mid-day trading on Wednesday, hitting $259.99. 6,564,085 shares of the stock were exchanged. The company has a market cap of $102.84 billion and a P/E ratio of 23.27. The company has a 50-day moving average price of $239.07 and a 200-day moving average price of $254.12. Allergan PLC has a one year low of $195.50 and a one year high of $340.34.
A number of equities analysts have recently weighed in on AGN shares. Leerink Swann reaffirmed a “buy” rating and set a $340.00 price target on shares of Allergan PLC in a research note on Tuesday, April 5th. Cowen and Company reaffirmed a “buy” rating on shares of Allergan PLC in a research note on Tuesday, April 5th. Nomura reaffirmed a “buy” rating and set a $330.00 price target (down from $350.00) on shares of Allergan PLC in a research note on Tuesday, April 5th. Canaccord Genuity reaffirmed a “buy” rating and set a $320.00 price target (down from $340.00) on shares of Allergan PLC in a research note on Thursday, March 31st. Finally, Deutsche Bank AG lowered their price objective on shares of Allergan PLC from $339.00 to $282.00 and set a “buy” rating on the stock in a research note on Wednesday, April 6th. Seven equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. Allergan PLC currently has a consensus rating of “Buy” and an average target price of $308.74.
In related news, CFO Maria Teresa Hilado bought 661 shares of Allergan PLC stock in a transaction that occurred on Thursday, June 2nd. The stock was purchased at an average cost of $241.57 per share, for a total transaction of $159,677.77. Following the acquisition, the chief financial officer now owns 11,957 shares in the company, valued at $2,888,452.49. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Nesli Basgoz sold 459 shares of the business’s stock in a transaction that occurred on Wednesday, May 11th. The stock was sold at an average price of $225.10, for a total value of $103,320.90. Following the completion of the sale, the director now owns 5,242 shares of the company’s stock, valued at $1,179,974.20. The disclosure for this sale can be found here.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
